Pantarhei Bioscience BV (PRB) is a limited liability company (Besloten Vennootschap) located in the Netherlands with an innovative approach towards drug development in Woman’s Health and Endocrine Cancer. PRB has developed a product pipeline based on its ability to identify and confirm novel medical uses of existing drugs, hormones, other endogenous human biologicals and combinations thereof.

The main areas of interest of PRB are contraception, menopausal hormone therapy (HT) and oncological applications such as breast cancer, prostate cancer and ovarian cancer.

The business concept of PRB is to develop patentable new treatment concepts using existing molecules up to proof-of-concept (PoC) in the human (phase II). Using known physiological targets and molecules often implies first confirmation of safety. The business model is based on the identification and patent protection of new opportunities, followed by internal project management and outsourcing of research and development activities. Once patent approval is received and supportive clinical data are generated, new concepts are licensed out of completion of clinical development (phase III), regulatory approval and sales and marketing.